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Abstract. Replication helps ensure that a genotype-phenotype associ-
ation observed in a genome-wide association (GWA) study represents
a credible association and is not a chance finding or an artifact due
to uncontrolled biases. We discuss prerequisites for exact replication,
issues of heterogeneity, advantages and disadvantages of different meth-
ods of data synthesis across multiple studies, frequentist vs. Bayesian
inferences for replication, and challenges that arise from multi-team
collaborations. While consistent replication can greatly improve the
credibility of a genotype-phenotype association, it may not eliminate
spurious associations due to biases shared by many studies. Conversely,
lack of replication in well-powered follow-up studies usually invalidates
the initially proposed association, although occasionally it may point to
differences in linkage disequilibrium or effect modifiers across studies.
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1. INTRODUCTION
Reproducibility has long been considered a key
part of the scientific method. In epidemiology, where
variable conditions are the rule, the repeated obser-
vation of associations between covariates by differ-
ent investigative teams, in different populations, us-
ing different designs and methods is typically taken
as evidence that the association is not an artifact
[22], for two principal reasons. First, repeated ob-
servation adds quantitative evidence that the asso-
ciation is not due to chance alone; second, replica-
tion across different designs and populations pro-
vides qualitative evidence that the association is not
due to uncontrolled bias affecting a single study.
Moreover, accumulated evidence can provide more
accurate estimates of the effect measures of the risk
factor being studied and their uncertainty.
Genetic epidemiology learned the importance of
replication the hard way. Before the advent of genome-
wide association (GWA) studies, most reported geno-
type-phenotype associations failed to replicate. There
were a number of reasons for these conflicting re-
sults, including the following: inappropriate reliance
on standard significance thresholds that did not take
the low prior probability of association into account,
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small sample sizes, and failure to measure the same
variant(s) across different studies [23, 27, 64]. In re-
sponse, the field moved toward more stringent re-
quirements for reporting associations, explicitly em-
phasizing replication [7]. Many high-profile journals
now will not publish genotype-phenotype associa-
tions without concrete evidence of replication [1].
In this article we review the requirements for repli-
cating associations discovered via GWA studies in
light of recent developments: in particular, the in-
creasing role of the consortia of multiple GWA stud-
ies. Prospective meta-analysis of multiple genome-
wide studies (conducted by different investigative
teams, in different populations, using different tech-
nologies and different designs) can satisfy the re-
quirement for replication in the context of gene dis-
covery, without the need to genotype yet more sam-
ples in yet further studies, as long as the combined
evidence for association is strong and consistent [71].
This is an important point, since very large sample
sizes are required to reliably identify common vari-
ants with modest effects, and formal replication of
an association—that is, genotyping the initially dis-
covered genetic variant in a new, completely inde-
pendent sample of sufficient size—may be too expen-
sive in terms of time, money and available samples.
Indeed, for some rare diseases (e.g., Creutzfeldt–
Jakob disease) or relatively uncommon diseases (e.g.,
pancreatic cancer), most if not all samples with
readily-available DNA may be genotyped as part of
initial GWA studies used at the discovery stage.
We describe the goals of replication and statistical
rules of thumb for distinguishing chance from true
associations in the first section of this article. We
then discuss the importance of exact replication—
seeing a consistent association with the same risk al-
lele using the same analytic methods across multiple
studies—and describe analytic methods for combin-
ing evidence across multiple studies, along with their
relative advantages and disadvantages. We close by
discussing why an association may fail to replicate
and place replication efforts in the wider picture of
contemporary genetic epidemiology, with its focus
on large-scale collaborations and data sharing.
2. GOALS OF REPLICATION
There are two primary reasons replication is es-
sential to confirm associations discovered via GWA
studies: to provide convincing statistical evidence
for association, and to rule out associations due to
biases. Another possible aim of replication is to im-
prove effect estimation.
2.1 Convincing Statistical Evidence for
Association
To date most individual GWA studies do not have
enough power to detect true associations at the con-
servative significance levels necessary to distinguish
false positives from false negatives. This point has
typically been made by referencing the large num-
ber of tests conducted in a GWA study and the con-
sequent severe adjustment of the p-value threshold
in order to control experiment-wide Type I error
rate. Empirical estimates of the threshold needed
to preserve the genome-wide Type I error rate in
studies of European-ancestry subjects using current
genotyping arrays range from 5× 10−7 to 1× 10−8
[18, 24, 51, 59]. These thresholds are different in
other populations; for example, they are even lower
in African or African–American samples, due to the
greater genetic diversity in these populations. Even
these stringent thresholds take into account only the
complexity of the genetic architecture, and they do
not adjust for the potential complexity of the pheno-
typic architecture, that is, when targeting multiple
phenotypes.
In the framework of the Bayes theorem, the prob-
ability that an observed association truly exists in
the sampled population depends not only on the ob-
served p-value for association, but also on the power
to detect the association (a function of minor al-
lele frequency, effect size and sample size), the prior
probability that the tested variant is associated with
the trait under study, and the anticipated effect size
[27, 64, 65]. We illustrate this in Figure 1, where we
plot the Bayes Factor for association (versus no as-
sociation) as a function of p-value, sample size and
minor allele frequency [29]. The Bayes Factor is the
ratio of the probability of the data under the alterna-
tive hypothesis (association with the tested variant)
to the probability of the data under the null hypoth-
esis (no association). (Others define the Bayes Fac-
tor as the inverse of this ratio [29].) The posterior
odds of true association given the data are equal
to the Bayes Factor times the prior odds of asso-
ciation. In Figure 1 the dashed line represents the
Bayes Factor needed to achieve posterior odds for an
association of 3 : 1, assuming prior odds of associa-
tion of 1 : 99,999 (i.e., roughly 100 out of 10,000,000
variants are truly associated with the studied trait).
Note that all p-values are not created equal: for a
given p-value, the evidence for association increases
with increasing sample size and depends on risk al-
lele frequency. Increasing overall sample size not only
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Fig. 1. The relationship between the Bayes Factor and p-value for different sample sizes and minor allele frequencies (left
panel: minor allele frequency of 40%; right panel: 5%). The dashed line represents the Bayes Factor necessary to achieve pos-
terior odds in favor of association of 3 : 1 or greater, assuming the prior odds of association are 1 : 99,999. Bayes Factors were
calculated for a case-control study with equal numbers of cases and controls, assuming the expected value of the absolute value
of the log odds ratio is log(1.15), and assuming a “spike and smear” prior. Calculations use equations (4) and (5) from [29],
with σ2 = I−1ββ − I
−1
αβ [I
−1
αα ]
−1I−1βα , where I is the Fisher information from simple logistic regression log(odds) = α+ βGadditive
calculated under the null (β = 0).
increases power to detect common risk variants with
modest effects, but it can also increase the cred-
ibility of the observed associations. Differences in
credibility by sample size for similar p-values are a
consequence of the fact that these calculations take
assumptions about the expected magnitude of the
true allelic odds ratio into account. In particular,
they assume that the true allelic odds ratio is un-
likely (probability < 2.1%) to be smaller than 0.5
or bigger than 2. Since small p-values can only be
achieved in small sample sizes if the estimated ef-
fect is large, these results are perceived to be less
credible in this framework.
In other words, the Bayes Factor and thus the
credibility of an association depends explicitly on
what we assume for the typical magnitude of likely
genetic effects. For example, if we assume that the
average effect is not an odds ratio of 1.15 as in Fig-
ure 1, but an odds ratio of ORav = 1.5, then the
prior odds of association will be less, because fewer
variants—with larger effects than in the ORav =
1.15 scenario—would suffice to explain the genetic
variability. A larger Bayes Factor would be needed to
reach a 3 : 1 posterior. Moreover, large effects emerg-
ing from small studies will be more credible than in
the ORav = 1.15 scenario, while very small effects
emerging with similar p-values from large studies
will be less credible [29].
Conversely, if we assume that the average effect
is an odds ratio of ORav = 1.02 (consistent with the
theory of infinitesimal effects, each having an almost
imperceptible contribution [14]), then the prior odds
of association will be much higher, because a much
larger set of (infinitesimally) associated variants are
anticipated and a smaller Bayes Factor would be
needed to reach a 3 : 1 posterior. Moreover, large ef-
fects emerging from small studies would be incredi-
ble, regardless of their p-value, while very small ef-
fects emerging with modest p-values from large stud-
ies would provide credible evidence for association.
We should acknowledge that the distribution of ef-
fect sizes of true associations is unknown, and there
is no guarantee that they would be similar for dif-
ferent traits. The difficulty of arriving at the true
causal variants (which may have larger effect sizes
than their markers) adds another layer of complex-
ity. Moreover, given simple power considerations, it
is expected that a large proportion of the large ef-
fects have been identified, while only a small pro-
portion of the smaller effects and a negligible pro-
portion of the tiny and infinitesimal effects are al-
ready discovered. With these caveats, most evidence
from GWA studies to date is more compatible with
the scenarios of ORav being in the range of 1.15
[45], but the 1.02 scenario is not implausible, and
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for some traits the 1.5 scenario may be operating,
but we still have not identified the true variants.
Many research groups cannot afford to genotype
the large sample sizes needed to reliably detect ge-
netic markers that are weakly associated with a trait
using a genome-wide platform. This has sparked in-
terest in multistage designs, where a subset of avail-
able samples are genotyped using the genome-wide
platform, and then a subset of the “most promis-
ing” markers (typically those with lowest p-values)
are genotyped using a custom platform. These de-
signs are reviewed in more detail elsewhere in this
issue [60]. We should note that the primary motiva-
tion of multistage designs is not to increase power
by testing fewer hypotheses in the second stage sam-
ples, and hence paying a smaller penalty for multi-
ple testing at the second stage. Rather the primary
goal of multistage designs is to save genotyping costs
or maximize power given a fixed genotyping bud-
get. If genotyping costs were not an issue, then the
multistage approach is less powerful than simply
testing all markers in the entire available sample
[33, 58, 60]. As genotyping costs decrease, and as
more samples have been genotyped as part of pre-
vious GWA analyses, single-stage analyses become
more common [33].
The appropriate threshold for claiming associa-
tion depends also on the context and the relative
costs for false positive and false negative results. For
example, re-sequencing a region and conducting in
vivo and in vitro functional studies is quite expen-
sive, and will require convincing evidence that the
observed association is true. On the other hand, in-
cluding a region in a predictive genetic risk score is
relatively inexpensive, so a less stringent threshold
might suffice. This approach to replication is intu-
itively Bayesian (although it need not use formal
Bayesian methods): each successive study serves to
update the prior for association in subsequent stud-
ies.
2.2 Ruling Out Association Due to Artifact
Even when the initial association is unlikely to be
a stochastic artifact due to multiple testing, it may
still be an artifact due to bias. For common vari-
ants, the anticipated effects are modest—for binary
traits, odds ratios smaller than 1.5; for continuous
traits, percent variance explained less than 0.5%—
and very similar in magnitude to the subtle biases
that may affect genetic association studies—most
notably population stratification bias. For this rea-
son, it is important to see the association in other
studies conducted using a similar (but not identical)
study base. In principle, careful design and anal-
ysis should eliminate or greatly reduce bias due to
population stratification in association studies using
unrelated individuals [17, 44, 52]—and, in practice,
these methods have effectively removed some wor-
rying systematic inflation in association statistics
[19]. Family-based designs can provide additional
evidence that an observed association is not due
to population stratification bias, but these designs
are not cost-efficient, and have their own unique
sources of bias. For example, nondifferential geno-
typing error can inflate Type I error rates in some
family-based analyses, although it does not change
the Type I error rate [47].
2.3 Improving Effect Estimates
Another reason to conduct replication studies is
to extend the generalizablity of the association. It
is important to know if the association exists and
has similar magnitude in different environmental or
genetic backgrounds. It is particularly interesting to
know how these associations play out in populations
of non-European ancestry, considering most GWA
studies to date have been conducted in European-
ancestry samples. Differences in allele frequencies
and local linkage disequilibrium (LD) patterns across
populations present both challenges and opportuni-
ties for replication and fine mapping. On the one
hand, a marker allele that is strongly associated with
a trait in one population may not have a detectable
association in another, as the allele frequency may
be smaller or the LD with the (unknown) causal
variant may be much weaker. Thus, initial replica-
tion studies should focus on populations with ge-
netic ancestry similar to that sampled in the study
that first observed the marker-trait association, us-
ing the exact strategy outlined in the next section.
Once credible evidence for this association has been
established, replication efforts in other populations
should type not only the marker known to be asso-
ciated in the original population, but other markers
that “tag” common variation in a region surround-
ing the marker. For fine mapping, differences in LD
patterns across populations—notably the lower lev-
els of LD in African-ancestry populations—might
lead to refined estimates of the position of causal
variants [55, 62].
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Replication may also be useful in identifying a
more reliable estimate of the effect size for the asso-
ciation. Signals selected based on statistical signifi-
cance thresholds in underpowered settings are likely
to have (on average) inflated effects due to the win-
ner’s curse phenomenon [28, 69, 70, 75]. Replication
should take this into account during the sample size
calculations for the replication efforts; the effect es-
timate from the initial study may be inflated, lead-
ing to an under-estimate of the number of subjects
needed to reliably detect it [69, 70, 75, 76]. Analytic
methods are available to adjust for winner’s-curse
bias, but studying the marker in additional samples
(beyond those used to initially identify the marker)
will help produce more unbiased estimates of the ge-
netic effect. Accurate estimates of marker risks are
important (even if the marker is only a surrogate for
the as yet unknown causal variant), as they may be
used for personalized predictive purposes [34, 68].
Finally, when there are several putative associa-
tion signals in a region of high LD, dense genotyp-
ing in replication studies may help elucidate whether
they represent independent loci, each with its own
effect in the trait, or whether one or all are “passen-
ger” markers, which have no effect conditional on
the true underlying causal variant. Detailed discus-
sion of fine mapping issues is beyond the scope of
this review, but in light of the effort involved, such
“fine mapping” efforts should arguably be reserved
for loci with credible evidence for association, for ex-
ample, loci with markers that have been replicated
exactly, as discussed in the next section [8].
3. PREREQUISITES FOR EXACT
REPLICATION OF A PUTATIVE
ASSOCIATION FROM A GWA STUDY
One of the early difficulties in replicating genetic
associations observed in candidate gene studies was
the fact that different groups would study different
markers in the same region. Because the LD among
these markers was poorly understood, results from
multiple studies could increase rather than decrease
confusion. The initial study may have seen an asso-
ciation with SNP A, but the second study did not
genotype that SNP, and instead saw an association
with SNP B, which was not genotyped in the original
study. As the number of SNPs typed per region in-
creased, “moving the goalposts” in this fashion con-
tributed to the problem of persistent false positives
in the candidate gene literature; by chance, some
SNP in the region (not necessarily the SNP that was
statistically significant in other studies) would have
p < 0.05, and this would be (incorrectly) proclaimed
replication [49]. In response to this problem, guide-
lines for replication in genetic association studies
now call for exact replication. The same marker—
or, if technical difficulties preclude this, a perfect or
near-perfect proxy for the original marker—should
be genotyped across all studies and analyzed using
the same genetic model. In this section we discuss
prerequisites for exact replication. We use the term
“exact replication” cautiously, recognizing that this
is an unattainable goal in epidemiology (e.g., stud-
ies conducted by different investigators at different
times, let alone places, will sample from different
populations) and that in some sense it is the “inex-
actness” of replication studies that increases credi-
bility of the observed association (it is less likely to
be an artifact due to a bias that is unique to the
initial study). We use the term to emphasize the
danger of “moving the goalposts” so far that claims
of replication carry little weight.
3.1 Test the Same Marker
This should be done preferably by directly geno-
typing this marker. Currently-available imputation
methods are powerful and quite accurate for filling
in information on missing common SNPs [12, 38,
39, 46, 50]. Even then, further confirmation by di-
rect genotyping would be very useful. (In fact, to
rule out technical artifact, some have argued that
an associated SNP should be genotyped using two
different genotyping technologies, or that a second
SNP in the region that is in [near-] perfect LD with
the associated SNP be genotyped [7].) Great caution
is needed when “replicating” an association by find-
ing an association with a (different) nearby marker:
if the new marker does not have perfect or almost
perfect LD with the previously discovered one, this
cannot be considered replication. Moreover, even for
markers with seemingly perfect LD in a given sam-
ple, the LD may be far less than perfect in a different
population and it may break completely in popula-
tions of different ancestry. When a panel of markers
spanning the whole locus is pursued (e.g., after rese-
quencing and fine mapping), different markers and
haplotypes may be found to be associated in dif-
ferent populations. Evidence from different markers
and haplotypes should not be combined in the same
meta-analysis. The consistency of each association
can be formally assessed separately (see the section
on statistical heterogeneity).
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3.2 Use the Same Analytic Methods
If the initial results found an increased risk per
copy of, say, the A allele (additive model), then a
significant increased risk for carriers of the T allele
(dominant model, in other direction) does not con-
stitute replication. It is in principle possible that the
direction of association can change due to differences
in linkage disequilibrium across study populations.
However, this “flip flop” phenomenon can occur only
in very specific situations that are unlikely when the
study populations have similar continental ancestry
[41]. The burden of proof is on investigators to show
evidence for how difference in LD in their study pop-
ulations could produce a “flip flop” if they wish to
claim replication, even though different alleles are
associated with risk. Merely citing the possibility of
“flip-flopping” does not suffice.
Other analytical options include the statistical
model (e.g., for a binary outcome, whether it is
treated as simply yes/no or the time-to-event is also
taken into account), the use of any covariates (e.g.
for age, gender or topic-specific variables) and the
use of corrections for relatedness. Usually, the im-
pact of these options is not major, but it can make
a difference for borderline associations which may
seem to pass or not pass a desired p-value threshold.
This means that both for GWA studies and subse-
quent investigations, one should carefully report the
methods in sufficient detail so they can be indepen-
dently replicated by other researchers [42].
Modeling can have a much more profound im-
pact in more complex associations than go beyond
single markers, for example, with approaches that
try to model dozens and hundreds of gene variants
that form a “pathway” [5, 35]. Such complex mod-
els may be built by MDR, kernel machines, step-
wise logistic regression or a diversity of other meth-
ods and it is important for the replication process
to use the same exact steps as the model build-
ing. Even then, because these models are so flexi-
ble, it is unclear whether a “significant” finding in a
second data set constitutes replication; the associa-
tion may be driven by different sets of SNPs in the
different studies. Researchers who conduct complex
model-selection/model-building analyses should re-
port their “final” model in as much detail as possi-
ble, so other investigators can judge the fit of that
model in other data sets.
3.3 Try to Use the Same Phenotype
For many traits, phenotype definitions may vary
considerably across studies, or there may be many
different options for defining the phenotypes of in-
terest within each study. Some of this variability is
unavoidable and results from differences in measure-
ment protocols across studies. For example, disease
may be self-reported in some studies or clinician-
diagnosed in others; waist:hip ratios may be self-
reported or measured in a clinic, using different op-
erational definitions of “waist”; etc. Characteristics
of studied phenotype may also differ across stud-
ies: for example, because of the widespread use of
Prostate-Specific Antigen (PSA) screening in the
United States since the early 1990s, the proportion
of early-stage prostate cancer cases in the US is
higher than in Europe, where PSA screening is not
as common. In the context of a prospective meta-
analysis, study investigators can discuss these issues
and reach consensus on how to define phenotype so
as to maximize relevant information while ensur-
ing as many studies can provide data as possible.
In general, there is a trade off between more accu-
rate (but more expensive and perhaps more inva-
sive) measurements on fewer people and less accu-
rate (but cheaper) measurements on more people.
For example, although the Fagerstom Test may be
a “gold standard” measure of nicotine dependence,
currently only a few studies with available genome-
wide genotype data have collected data on this test;
on the other hand, many studies have collected in-
formation about the number of cigarettes smoked
per day (a component of the Fagerstrom score) [6].
To maximize sample size, investigators may agree to
analyze cigarettes per day (which then raises further
issues such as what scale to use, whether and how
to transform the raw data, how to reconcile contin-
uous with categorical data, etc.). Prospective meta-
analyses for height, BMI and fasting glucose have
dealt with the issue of phenotype harmonization in
a trait-by-trait basis [37, 43, 53, 67]. Other consortia
and projects such as the Public Population Project
in Genomics (http://www.p3gconsortium.org/)
and PhenX (www.phenx.org) aim to facilitate broad
collaboration among existing and future genome-
wide association studies by making recommenda-
tions for standard phenotyping protocols for many
diseases and traits. Still, despite best efforts to har-
monize measures, some measurement differences
across studies will persist, and investigators should
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be aware of these as possible sources of heterogene-
ity (see Sections 4 and 5).
Requiring that replication studies use the same
phenotype definition used in the initial study also
helps avoid false positives due to “data dredging,”
the temptation to generate small p-values by testing
many different traits (different case subtypes, con-
tinuous traits dichotomize using different, arbitrary
cut points, etc.) [27]. When many phenotypes or
phenotype definitions and analyses are used, there
should be a penalty for multiple testing. Applying
this penalty is not always straightforward, given that
most of the phenotypes and analyses are usually cor-
related or even highly correlated. However, the dan-
ger exists for an association to be claimed replicated,
after searching through repeated modifications of
the phenotypes and analyses thereof. A p-value that
has been obtained through such an iterative search-
ing path is not the same as one that was obtained
from a single main analysis of a single phenotype.
4. REPLICATION METHODS AND
PRESENTATION OF RESULTS
4.1 Statistical Heterogeneity Across Datasets
There are several tests and metrics of between-
dataset heterogeneity, borrowed from applications
of meta-analysis in other fields. The most popular
are Cochran’s Q test of homogeneity [9], the I2 met-
ric [obtained by (Q-degrees of freedom)/Q] and the
between-study variance estimator τ2 [21]. There are
shortcomings to all of them [26]. The Q test is un-
derpowered in the common situation where there are
few datasets and may be overpowered when there
are many, large datasets. There are now readily-
available approaches that can be used to compute
the power of the Q test to detect a given tau-squared
[4]. When the Q test is underpowered, the I2 met-
ric has large uncertainty and this can be readily vi-
sualized by computing its 95% confidence intervals
[30]. Similarly, estimates of τ2 may have large uncer-
tainty. One potentially useful approach may be to
estimate the magnitude of between-study variabil-
ity compared with the observed effect size θ, that
is, h = τ/θ. For a small effect size, even small τ2
may question the generalizability of the conclusion
that there is an association across all datasets. This
conclusion would not be as easily challenged in the
presence of a large effect size.
Some other caveats should be mentioned. The win-
ner’s curse in the magnitude of the effect in the dis-
covery phase may introduce spuriously inflated het-
erogeneity, when the discovery data are combined
with subsequent replication studies. In such two-
stage approaches, between-study heterogeneity
should best be estimated excluding the discovery
data. Conversely, if all datasets are measured with
genome-wide platforms and GWA scan meta-analysis
is performed in all gene variants, this is no longer
an issue. In fact, if the GWA scan meta-analysis
uses random effects (see below), the emerging top
hits from the GWA scan meta-analysis are likely
to have, on average, deflated observed heterogene-
ity compared with the true heterogeneity. This is
because underestimation of the between-study het-
erogeneity favors a variant to come to the top of the
list, since it does not get penalized by wider confi-
dence intervals in the random effects setting.
However, we caution that when the number of
studies is relatively small, association tests based
on random-effects meta-analysis may be deflated, as
the between-study variance τ2 will be poorly esti-
mated. This is illustrated in Figure 2, which shows
quantile-quantile plots for fixed-effect and random-
effects meta-analyses of data from PanScan collabo-
ration, which involves 13 studies in the initial GWAS
scan. For the random effects analysis, the genomic-
control “inflation factor” is in this case more aptly
named a “deflation factor”: λGC = 0.84, indicating
that the random effects p-values are larger than ex-
pected under the assumption that the vast major-
ity of SNPs are not associated with pancreatic can-
cer. Fixed-effect meta analysis is arguably more ap-
propriate as an initial screening test for associated
markers, although because fixed-effect analysis can
be highly significant when only one (relatively large)
study shows evidence for association, analyses that
incorporate effect heterogeneity such as random ef-
fects meta-analysis should be reported for highly sig-
nificant markers from fixed-effect analyses.
Finally, lack of demonstrable heterogeneity may
be perceived as a criterion of credible replication
[31]. However, one should note that tests and mea-
sures of heterogeneity address whether effect sizes
across different datasets vary, not whether they are
consistently on the same side of the null. Dataset-
specific effects could vary a lot, but they may all
still point to the same direction of effect. Given the
potential diversity of LD structure across popula-
tions, and differences in phenotype definitions and
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Fig. 2. Quantile-quantile plots for fixed-effect and random–
effect meta-analyses of the 13 studies in the initial PanScan
genome-wide association study of pancreatic cancer. The ge-
nomic control inflation factors λGC for the fixed-effect and
random effect analyses were 0.84 and 1.00, respectively. λGC
was calculated as the median observed chi-squared test statis-
tic divided by the median of a chi-squared distribution with
one degree of freedom.
measurements across studies, between-study hetero-
geneity should not dismiss an association because
the effect sizes are not consistent, if the evidence for
rejection of the null hypothesis is strong.
4.2 Models for Synthesis of Data from Multiple
Replication Studies
Data across studies can be combined at the level
of either p-values (probability pooler methods) or
effect sizes (effect size meta-analysis) [12, 32, 61].
When p-values are combined, at a minimum one
should take into account also the direction of effects,
but the magnitude of the effects is not taken into
account. When effect sizes are used, there are sev-
eral models that can be used, depending on whether
between-study heterogeneity is taken into account or
not, and if the former, how this is done. In general,
fixed effects approaches that ignore between-study
heterogeneity are better powered than random ef-
fects approaches and thus more efficient for discov-
ery purposes. However, there is a trade-off for in-
creased chances of false-positives. For effect estima-
tion and predicting what effects might be expected
in future similar populations, random effects are in-
tuitively superior in capturing better the extent of
the uncertainty. Commonly, random effects are esti-
mated with a 95% CI that captures the uncertainty
about the mean effect, but ideally one should also
examine the uncertainty of the distribution of effects
across populations. This is provided by the predic-
tion interval. An approximate (1 − α)% prediction
interval for the effect in an unspecified study can be
obtained from the estimate of the mean effect µˆ ,
its estimated standard error and the estimate of the
between-study variance τˆ2 by
µˆ± tαk−2√{τˆ2 + ŜE(µˆ)2},
where tα
k−2
is the 100(1 − α/2)% percentile of the
t-distribution with k − 2 degrees of freedom [20]. It
becomes implicit that when an association has been
probed in only a few datasets, then the prediction
interval will be wider than the respective confidence
interval, even if there is no demonstrable between-
study variance (i.e., τ2 = 0). Table 1 summarizes
some issues that arise in selecting, interpreting and
comparing the properties and results of various com-
monly used meta-analyses methods.
5. REASONS FOR NONREPLICATION
[T]here are often two or more hypothe-
ses which account for all the known facts
on some subject, and although, in such
cases, men [sic] of science endeavour to
find facts which will rule out all the hy-
potheses except one, there is no reason why
they should always succeed. — Bertram
Russell [54]
A variant observed to be associated with a trait
in an initial GWA may not be associated with the
trait in subsequent studies, even though the original
association was (nearly) “genome-wide significant.”
There are a number of potential reasons for this non-
replication.
(a) The original observation was a false positive
due to sampling error. This is the default explana-
tion, until proven otherwise. This is more likely for
associations that were not (or just barely) “genome-
wide significant” than for observations that were ex-
tremely statistically significant.
(b) The follow-up study had insufficient power.
This problem can be avoided by ensuring the follow-
up study is large enough to reliably detect the ob-
served effect (after accounting for inflation due to
“winner’s curse”) [69, 70, 75, 76]. Moreover, if we
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Table 1
Different methods for meta-analysis in the genome-wide association setting
Issues and caveats P-value Effect size meta-analysis
meta-analysis
Fixed effects Random effects
Direction of effect is consid-
ered
In some methods Yes Yes
Effect size is considered No Yes Yes
Summary p-value is obtained Yes Yes Yes
Summary effect is obtained No Yes Yes
Summary result can be
converted to credibility based
on priors for the anticipated
effect sizes
No Yes Yes
Between-study heterogeneity
can be taken into account
No No Yes
Between-study heterogeneity
can be estimated/tested
No Yes Yes
Consensus on if/how datasets
should be weighted
No Yes Yes
Commonly used weights None, SQRT(N), N Inverse vari-
ance
Inverse vari-
ance
Prior assumptions on the effect
size can be used
No In Bayesian
meta-analysis
In Bayesian
meta-analysis
Prior uncertainty on
heterogeneity can be
accommodated
No No In Bayesian
meta-analysis
Prior uncertainty on the ge-
netic model can be accommo-
dated
No In Bayesian
M-A
In Bayesian
meta-analysis
Normality assumptions typically
made within each study
Yes Yes Yes
Normality assumptions within
each study easily testable
Yes, rarely done Yes, rarely
done
Normality assumptions for
distribution of effects across
studies easily testable
No effects assumed Single common
effect assumed
(assumption
may be visibly
wrong)
Not easily
testable
Heavy-tail alternative methods
exist
No Yes, rarely
used
Yes, rarely
used
Use with uncommon alleles
(small genotype groups, or
even zero allele counts in
2× 2 tables)
Need to use exact methods Quite robust Between-study
variance
estimation
unstable
Power for discovery Good Good Less than oth-
ers
False-positives from single
biased dataset
Susceptible Susceptible Less suscepti-
ble
False-positives when evidence
from small studies is most
biased
Susceptible Susceptible More suscepti-
ble
False-positives when evidence
from large studies is most biased
Susceptible Susceptible Less suscepti-
ble
Can predict range of effect sizes
in future similar populations
No Too narrow
confidence
intervals
Appropriate
with predictive
intervals
Can convey uncertainty for
practical applications (e.g., to
be used in clinical prediction
test)
Useless Inappropriate Most ap-
propriate
with prediction
intervals
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consider the cumulative evidence (both the original
data plus the follow-up data) as an updated meta-
analysis, the cumulative evidence may still pass
genome-wide significance or a sufficient Bayes Fac-
tor threshold, even though the follow-up data are
not formally (highly) significant, when seen in iso-
lation.
(c) The genotypic coding used in the initial study
may not accurately reflect the true underlying asso-
ciation, leading to a loss of power. Ideally the follow-
up study should be well powered to detect associa-
tions based on different genetic models (e.g., reces-
sive, dominant) that are consistent with the results
observed in the first study.
(d) The variant may be a poor marker for the
trait due to differences in linkage-disequilibrium
structure between the studies. This is more likely
if the study populations have different ethnic back-
grounds. When discussing this as a possible rea-
son for nonreplication, investigators should make a
good-faith effort to provide empirical data on how
linkage-disequilibrium patterns differ (e.g., using
HapMap data) and how these differences would lead
to inconsistencies across studies.
(e) Differences in design or trait definition may
lead to inconsistencies. See Sections 6.1 and 6.2 for
examples of how different matching or ascertain-
ment schemes can affect estimates of marker-trait
association. Again, when citing this as a reason for
nonreplication, investigators should as far as possi-
ble present arguments for the likelihood and mag-
nitude of differences due to design or measurement
differences.
(f) The absence of an association in the subse-
quent studies may be due to true etiologic hetero-
geneity. Sometimes, this may be driven by gene–gene
or gene–environment interaction. If cases in the orig-
inal study were required to have a family history of
disease, for example, or required to have a relatively
rare exposure profile (e.g., male lifetime never smok-
ers), then subsequent studies that do not impose
these restrictions may not see the association, if the
association is restricted to subgroups with a par-
ticular genetic or exposure background. However,
to date, gene–gene and gene–environment interac-
tions have been notoriously difficult to document
robustly.
For the last three explanations, it is useful to clar-
ify if the explanation was offered a posteriori af-
ter observing the inconsistent results in different
studies. Post hoc explanations for subgroup differ-
ences, interactions and effect modification may be
overfit to the observed data and may require fur-
ther prospective replication in further datasets be-
fore they can be relied upon.
6. THE WIDER PICTURE OF REPLICATION
EFFORTS: CONSORTIA, DATA AVAILABILITY
AND FIELD SYNOPSES
With the recent successes of GWA studies, the
field has realized that increasingly large sample sizes
are required to identify and replicate the increas-
ingly small effect sizes at common variants that re-
main undetected. Even wider networks will be re-
quired to facilitate the study of variation at the
lower end of the frequency spectrum (be it single
base changes, copy number variants or otherwise).
Collaboration and data sharing are invaluable tools
in achieving the necessary sample sizes for
well-powered replication studies. The past few years
have witnessed a rapid rise in international con-
sortium formation and collaboration has taken a
most prominent role in conducting research. Consor-
tia allow investigators to make some design choices
up front (if only deciding which SNPs to attempt
to replicate), and to work together to harmonize
phenotypes and analyses [71]. Several examples of
notable successes of consortium-coordinated efforts
have started to emerge in the literature [2, 10, 66,
67, 74].
In silico replication of association signals has been
further facilitated by initiatives making genetic asso-
ciation study results and/or raw data publicly avail-
able (or available through application to an access
committee), for example, the Wellcome Trust Case
Control Consortium (www.wtccc.org.uk), dbGAP
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap)
and the European Genotype Archive (EGA,
http://www.ebi.ac.uk/ega). Several emerging con-
siderations, for example, with respect to the
anonymity of data [25], avenues for communication
between primary investigators and secondary users
to facilitate a better understanding of the datasets
and their appropriate uses, and suitable accredita-
tion of involved parties, require resolution in order
to optimize the use of publicly available raw data.
Replication undoubtedly constitutes an evolving
practice. The need to incorporate new data aris-
ing from further GWA scans, other replication stud-
ies, meta-analyses or all of the above leads to the
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Table 2
Cumulative power to detect association (α= 5× 10−8) at a risk allele with frequency 0.20 and 0.40, and allelic odds ratios of
1.1 and 1.2, given sample sizes for the WTCCC, DGI and FUSION studies
Studies Risk allele Allelic Cumulative n Cumulative n Power
frequency odds ratio cases controls
WTCCC 0.20 1.10 1924 2938 0.0002
WTCCC+DGI 0.20 1.10 3388 4405 0.0011
WTCCC+DGI+FUSION 0.20 1.10 4549 5579 0.0033
WTCCC 0.40 1.10 1924 2938 0.0007
WTCCC+DGI 0.40 1.10 3388 4405 0.0054
WTCCC+DGI+FUSION 0.40 1.10 4549 5579 0.0166
WTCCC 0.20 1.20 1924 2938 0.0333
WTCCC+DGI 0.20 1.20 3388 4405 0.2078
WTCCC+DGI+FUSION 0.20 1.20 4549 5579 0.4426
WTCCC 0.40 1.20 1924 2938 0.1336
WTCCC+DGI 0.40 1.20 3388 4405 0.5468
WTCCC+DGI+FUSION 0.40 1.20 4549 5579 0.8219
emerging paradigm of conglomerate analyses. Field
synopses, for example, are efforts to integrate data
from diverse sources (GWA studies, consortia, sin-
gle published studies) in the published literature
and to make them publicly available in electronic
databases that can be updatable. Examples include
the field synopses on Alzheimer’s disease (AlzGene
database), schizophrenia (SzGene database) and
DNA repair genes [3, 63]. The results of the meta-
analyses on the accumulated data can then also be
graded for their epidemiological credibility, for ex-
ample, as proposed by the Venice criteria [31].
6.1 Example from the Field of Type 2 Diabetes
Researchers in the field of Type 2 diabetes (T2D)
genetics were among the first to lead the way in
distributed collaborative networks, exemplified by
early efforts such as the International Type 2 Dia-
betes Linkage Analysis Consortium and the Inter-
national Type 2 Diabetes 1q Consortium [11, 16,
72]. The advent of GWA scans was met by pre-
publication data sharing between three large-scale
studies, the WTCCC, DGI and FUSION scans [56,
57, 59, 73], leading to the formation of the DIA-
GRAM Consortium (Diabetes Genetics Replication
and Meta-analysis). By exchanging information on
top signals, the three studies obtained in silico repli-
cation of individual scan findings and then further
pursued de novo replication in additional sets of in-
dependent samples. This endeavor additionally high-
lighted examples of statistical heterogeneity across
the studies, notably with respect to one of the
WTCCC study’s strongest signals, residing within
the FTO gene [13]. This inconsistency in observed
associations could be ascribed to study design and,
specifically, to matching cases and controls for BMI
(DGI study). The FTO signal was quickly identi-
fied as the first robustly replicating association with
obesity, mediating its effect on T2D through BMI. A
truly genome-wide meta-analysis of the three scans
ensued, with large-scale replication efforts in inde-
pendent datasets of T2D cases and controls, all of
European origin. This effort led to the identification
of further novel T2D susceptibility loci [74]. Table 2
demonstrates the gains in power afforded by increas-
ing sample size from a single scan to the synthesis
of all three studies for a realistic common complex
disease susceptibility locus.
6.2 Anthropometrics and the Analysis of
“Secondary Traits”
The meta-analyses of body mass index and height
conducted by the Genetic Investigation of ANthro-
pometric Traits (GIANT) consortium raised addi-
tional issues [36, 43, 67]. Specifically, unlike the dia-
betes consortia, where each participating study was
designed with diabetes as its primary outcome, the
studies involved in GIANT were not originally de-
signed to study determinants of BMI and height,
rather they were originally case-control studies of
diabetes, prostate and breast cancers, and other dis-
eases [15, 40]. In principle, if the studied trait is
associated with disease risk, then conditioning on
case-control status can create a spurious association
between a marker and the trait. In practice, only a
small number of markers will have an inflated Type
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I error rate—namely, those markers that are asso-
ciated with disease risk but not directly with the
secondary trait—and the magnitude of the inflation
depends on both the strength of the association be-
tween the secondary trait and disease (which could
be modest or controversial, as in the case of smok-
ing and breast or prostate cancer, or quite strong,
as in the case of BMI and T2D or smoking and lung
cancer) and the strength of the association between
the marker and disease (typically relatively weak)
[15, 48]. Moreover, the risk of false positives may be
further ameliorated by diversity of designs among
the participating studies—some may have originally
been case-control studies of different diseases, oth-
ers may have been cohort or cross-sectional stud-
ies. Although there are analytic methods that can
eliminate spurious association or bias due to case-
control ascertainment in particular situations and
under particular assumptions [40, 48], these should
not replace careful consideration of potential biases
and evaluation of heterogeneity in effect measures
across studies with different designs.
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